Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Monday, January 8, 2024 at 11:15 a.m. PT (2:15 p.m. ET).

A live webcast of the presentation will be available on the Events and Presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Neumora Contact:
Helen Rubinstein
315-382-3979
Helen.Rubinstein@neumoratx.com

Staff

Recent Posts

FendX Announces Sixth Real-World Testing Site for REPELWRAP(TM) Film with LA Fitness

Real-World testing nanotechnology to provide insights for manufacturing process with DunmoreOakville, Ontario--(Newsfile Corp. - July…

1 hour ago

CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe

CordenPharma is making a record investment of ~€900m over the next 3 years in expanding…

2 hours ago

Masimo Files Complaint Seeking Injunction Requiring Politan to Correct Material Misstatements

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI), a global leader in noninvasive…

5 hours ago

SamanTree Medical Raises $14M in Series B Financing Round to Support Global Expansion and Innovation in Surgical Treatment

Henry Charlton and Claire Poulard to join the Board of Directors Funding will Accelerate US…

5 hours ago